Literature DB >> 18273057

Role of IL-2 secreted by PADRE-specific CD4+ T cells in enhancing E7-specific CD8+ T-cell immune responses.

D Kim1, A Monie, L He, Y-C Tsai, C-F Hung, T-C Wu.   

Abstract

CD4(+) T helper cells are known to play an integral role in the generation of CD8(+) T-cell immune responses. We have previously shown that co-administration of DNA vaccines containing E6 or E7 protein of human papillomavirus 16 (HPV-16) combined with DNA encoding invariant (Ii) chain in which class II-associated Ii peptide (CLIP) region is replaced with the CD4(+) T helper epitope, PADRE (Pan-DR-epitope) (Ii-PADRE DNA) enhanced HPV antigen-specific CD8(+) T-cell immune responses in vaccinated mice. In the current study, we investigated the enhancement of HPV E7-specific CD8(+) T-cell immune responses by PADRE-specific CD4(+) T cells. We showed that intradermal administration of Ii-PADRE DNA at the same location as E7-expressing DNA is necessary to generate strong E7-specific CD8(+) T-cell immune responses. We also showed that PADRE-specific CD4(+) T cells generated by Ii-PADRE DNA vaccination expressed Th1 cytokine profile. Furthermore, our in vitro study demonstrated that PADRE-specific CD4(+) T cells stimulated with PADRE-loaded dendritic cells secrete IL-2 that leads to the proliferation of E7-specific CD8(+) T cells. Thus, our data suggest that activated PADRE-specific CD4(+) T helper cells may be required at the vicinity of E7-specific CD8(+) T cells where they secrete IL-2, which enhances the E7-specific CD8(+) T-cell immune responses generated by DNA vaccination.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18273057      PMCID: PMC3066096          DOI: 10.1038/sj.gt.3303102

Source DB:  PubMed          Journal:  Gene Ther        ISSN: 0969-7128            Impact factor:   5.250


  25 in total

1.  Dynamics of CD8+ T cell priming by dendritic cells in intact lymph nodes.

Authors:  Philippe Bousso; Ellen Robey
Journal:  Nat Immunol       Date:  2003-05-05       Impact factor: 25.606

Review 2.  Helping the CD8(+) T-cell response.

Authors:  Michael J Bevan
Journal:  Nat Rev Immunol       Date:  2004-08       Impact factor: 53.106

3.  DNA-based immunization by in vivo transfection of dendritic cells.

Authors:  C Condon; S C Watkins; C M Celluzzi; K Thompson; L D Falo
Journal:  Nat Med       Date:  1996-10       Impact factor: 53.440

4.  Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules.

Authors:  Z Shen; G Reznikoff; G Dranoff; K L Rock
Journal:  J Immunol       Date:  1997-03-15       Impact factor: 5.422

Review 5.  DNA vaccines.

Authors:  J J Donnelly; J B Ulmer; J W Shiver; M A Liu
Journal:  Annu Rev Immunol       Date:  1997       Impact factor: 28.527

6.  Linked recognition of helper and cytotoxic antigenic determinants for the generation of cytotoxic T lymphocytes.

Authors:  D Cassell; J Forman
Journal:  Ann N Y Acad Sci       Date:  1988       Impact factor: 5.691

7.  Three-cell-type clusters of T cells with antigen-presenting cells best explain the epitope linkage and noncognate requirements of the in vivo cytolytic response.

Authors:  N A Mitchison; C O'Malley
Journal:  Eur J Immunol       Date:  1987-11       Impact factor: 5.532

8.  Development of high potency universal DR-restricted helper epitopes by modification of high affinity DR-blocking peptides.

Authors:  J Alexander; J Sidney; S Southwood; J Ruppert; C Oseroff; A Maewal; K Snoke; H M Serra; R T Kubo; A Sette
Journal:  Immunity       Date:  1994-12       Impact factor: 31.745

9.  Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen.

Authors:  K Y Lin; F G Guarnieri; K F Staveley-O'Carroll; H I Levitsky; J T August; D M Pardoll; T C Wu
Journal:  Cancer Res       Date:  1996-01-01       Impact factor: 12.701

10.  Induction of a CD8+ cytotoxic T lymphocyte response by cross-priming requires cognate CD4+ T cell help.

Authors:  S R Bennett; F R Carbone; F Karamalis; J F Miller; W R Heath
Journal:  J Exp Med       Date:  1997-07-07       Impact factor: 14.307

View more
  10 in total

1.  Single chain MHC I trimer-based DNA vaccines for protection against Listeria monocytogenes infection.

Authors:  Sojung Kim; Adam Zuiani; Javier A Carrero; Ted H Hansen
Journal:  Vaccine       Date:  2012-01-26       Impact factor: 3.641

2.  Therapeutic DNA Vaccines for Human Papillomavirus and Associated Diseases.

Authors:  Max A Cheng; Emily Farmer; Claire Huang; John Lin; Chien-Fu Hung; T-C Wu
Journal:  Hum Gene Ther       Date:  2018-03-16       Impact factor: 5.695

3.  DNA vaccines for cervical cancer.

Authors:  Chien-Fu Huang; Archana Monie; Wei-Hung Weng; Tc Wu
Journal:  Am J Transl Res       Date:  2010-01-02       Impact factor: 4.060

Review 4.  Immunotherapy for cervical cancer: Research status and clinical potential.

Authors:  Jun-Han Su; Anjui Wu; Elizabeth Scotney; Barbara Ma; Archana Monie; Chien-Fu Hung; T-C Wu
Journal:  BioDrugs       Date:  2010-04-01       Impact factor: 5.807

Review 5.  Peptide vaccines in cancer-old concept revisited.

Authors:  Takumi Kumai; Hiroya Kobayashi; Yasuaki Harabuchi; Esteban Celis
Journal:  Curr Opin Immunol       Date:  2016-12-09       Impact factor: 7.486

Review 6.  Therapeutic HPV DNA vaccines.

Authors:  Ken Lin; Elena Roosinovich; Barbara Ma; Chien-Fu Hung; T-C Wu
Journal:  Immunol Res       Date:  2010-07       Impact factor: 2.829

7.  Enhancement of CD4+ T-cell help reverses the doxorubicin-induced suppression of antigen-specific immune responses in vaccinated mice.

Authors:  D Kim; A Monie; Y-C Tsai; L He; M-C Wang; C-F Hung; T-C Wu
Journal:  Gene Ther       Date:  2008-05-08       Impact factor: 5.250

8.  Pitfalls of vaccinations with WT1-, Proteinase3- and MUC1-derived peptides in combination with MontanideISA51 and CpG7909.

Authors:  Jürgen Kuball; Karin de Boer; Eva Wagner; Mohammed Wattad; Edite Antunes; Risini D Weeratna; Alain P Vicari; Carina Lotz; Suzanne van Dorp; Samantha Hol; Philip D Greenberg; Wolfgang Heit; Heather L Davis; Matthias Theobald
Journal:  Cancer Immunol Immunother       Date:  2010-10-21       Impact factor: 6.968

9.  Innovative DNA vaccine for human papillomavirus (HPV)-associated head and neck cancer.

Authors:  A Wu; Q Zeng; T H Kang; S Peng; E Roosinovich; S I Pai; C-F Hung
Journal:  Gene Ther       Date:  2010-10-28       Impact factor: 5.250

10.  Cancer immunotherapy employing an innovative strategy to enhance CD4+ T cell help in the tumor microenvironment.

Authors:  Liwen Song; Ming-Chieh Yang; Jayne Knoff; T-C Wu; Chien-Fu Hung
Journal:  PLoS One       Date:  2014-12-22       Impact factor: 3.240

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.